We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The contract development and manufacturing organization (CDMO) Enteris BioPharma received a $10 million milestone payment from Cara Therapeutics related to the license agreement for the Peptelligence oral formulation technology utilized in ...